579 related articles for article (PubMed ID: 29159043)
1. Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome.
Neale N; Padilla C; Fonseca LM; Holland T; Zaman S
Neuroimage Clin; 2018; 17():263-271. PubMed ID: 29159043
[TBL] [Abstract][Full Text] [Related]
2. PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome.
Zammit MD; Tudorascu DL; Laymon CM; Hartley SL; Zaman SH; Ances BM; Johnson SC; Stone CK; Mathis CA; Klunk WE; Cohen AD; Handen BL; Christian BT
Neuroimage; 2021 Mar; 228():117728. PubMed ID: 33421595
[TBL] [Abstract][Full Text] [Related]
3. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
Rafii MS; Lukic AS; Andrews RD; Brewer J; Rissman RA; Strother SC; Wernick MN; Pennington C; Mobley WC; Ness S; Matthews DC;
J Alzheimers Dis; 2017; 60(2):439-450. PubMed ID: 28946567
[TBL] [Abstract][Full Text] [Related]
4. Secondary prevention of Alzheimer's dementia: neuroimaging contributions.
Ten Kate M; Ingala S; Schwarz AJ; Fox NC; Chételat G; van Berckel BNM; Ewers M; Foley C; Gispert JD; Hill D; Irizarry MC; Lammertsma AA; Molinuevo JL; Ritchie C; Scheltens P; Schmidt ME; Visser PJ; Waldman A; Wardlaw J; Haller S; Barkhof F
Alzheimers Res Ther; 2018 Oct; 10(1):112. PubMed ID: 30376881
[TBL] [Abstract][Full Text] [Related]
5. Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome.
Rafii MS
Dev Neurobiol; 2019 Jul; 79(7):711-715. PubMed ID: 30536948
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer-Related Cerebrovascular Disease in Down Syndrome.
Lao PJ; Gutierrez J; Keator D; Rizvi B; Banerjee A; Igwe KC; Laing KK; Sathishkumar M; Moni F; Andrews H; Krinsky-McHale S; Head E; Lee JH; Lai F; Yassa MA; Rosas HD; Silverman W; Lott IT; Schupf N; Brickman AM
Ann Neurol; 2020 Dec; 88(6):1165-1177. PubMed ID: 32944999
[TBL] [Abstract][Full Text] [Related]
7. Contribution of neuroimaging to the diagnosis of Alzheimer's disease and vascular dementia.
Román G; Pascual B
Arch Med Res; 2012 Nov; 43(8):671-6. PubMed ID: 23142262
[TBL] [Abstract][Full Text] [Related]
8. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.
Thal DR; Attems J; Ewers M
J Alzheimers Dis; 2014; 42 Suppl 4():S421-9. PubMed ID: 25227313
[TBL] [Abstract][Full Text] [Related]
9. Associations between white matter microstructure and amyloid burden in preclinical Alzheimer's disease: A multimodal imaging investigation.
Racine AM; Adluru N; Alexander AL; Christian BT; Okonkwo OC; Oh J; Cleary CA; Birdsill A; Hillmer AT; Murali D; Barnhart TE; Gallagher CL; Carlsson CM; Rowley HA; Dowling NM; Asthana S; Sager MA; Bendlin BB; Johnson SC
Neuroimage Clin; 2014; 4():604-14. PubMed ID: 24936411
[TBL] [Abstract][Full Text] [Related]
10. Selective Impairment of Long-Range Default Mode Network Functional Connectivity as a Biomarker for Preclinical Alzheimer's Disease in People with Down Syndrome.
DiProspero ND; Keator DB; Phelan M; van Erp TGM; Doran E; Powell DK; Van Pelt KL; Schmitt FA; Head E; Lott IT; Yassa MA
J Alzheimers Dis; 2022; 85(1):153-165. PubMed ID: 34776436
[TBL] [Abstract][Full Text] [Related]
11. AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome.
Hartley SL; Handen B; Tudorascu D; Lee L; Cohen A; Schworer EK; Peven JC; Zammit M; Klunk W; Laymon C; Minhas D; Luo W; Zaman S; Ances B; Preboske G; Christian BT;
Alzheimers Dement; 2024 Jan; 20(1):366-375. PubMed ID: 37641428
[TBL] [Abstract][Full Text] [Related]
12. Weight Loss and Alzheimer's Disease in Down Syndrome.
Fleming V; Helsel BC; Ptomey LT; Rosas HD; Handen B; Laymon C; Christian BT; Head E; Mapstone M; Lai F; Krinsky-McHale S; Zaman S; Ances BM; Lee JH; Hartley SL;
J Alzheimers Dis; 2023; 91(3):1215-1227. PubMed ID: 36565120
[TBL] [Abstract][Full Text] [Related]
13. Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia.
Sabbagh MN; Chen K; Rogers J; Fleisher AS; Liebsack C; Bandy D; Belden C; Protas H; Thiyyagura P; Liu X; Roontiva A; Luo J; Jacobson S; Malek-Ahmadi M; Powell J; Reiman EM
Alzheimers Dement; 2015 Aug; 11(8):994-1004. PubMed ID: 25849033
[TBL] [Abstract][Full Text] [Related]
14. Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease.
Sintini I; Schwarz CG; Martin PR; Graff-Radford J; Machulda MM; Senjem ML; Reid RI; Spychalla AJ; Drubach DA; Lowe VJ; Jack CR; Josephs KA; Whitwell JL
Hum Brain Mapp; 2019 Apr; 40(5):1618-1631. PubMed ID: 30549156
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET for Prediction of AD Dementia in Mild Cognitive Impairment. A Review of the State of the Art with Particular Emphasis on the Comparison with Other Neuroimaging Modalities (MRI and Perfusion SPECT).
Sanchez-Catasus CA; Stormezand GN; van Laar PJ; De Deyn PP; Sanchez MA; Dierckx RA
Curr Alzheimer Res; 2017; 14(2):127-142. PubMed ID: 27357645
[TBL] [Abstract][Full Text] [Related]
16. Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism.
Smailovic U; Koenig T; Savitcheva I; Chiotis K; Nordberg A; Blennow K; Winblad B; Jelic V
Brain Connect; 2020 Dec; 10(10):555-565. PubMed ID: 33073602
[No Abstract] [Full Text] [Related]
17. Optimizing Use of Neuroimaging Tools in Evaluation of Prodromal Alzheimer's Disease and Related Disorders.
Raji CA; Torosyan N; Silverman DHS
J Alzheimers Dis; 2020; 77(3):935-947. PubMed ID: 32804147
[TBL] [Abstract][Full Text] [Related]
18. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
19. Neuroimaging of Alzheimer's disease: focus on amyloid and tau PET.
Matsuda H; Shigemoto Y; Sato N
Jpn J Radiol; 2019 Nov; 37(11):735-749. PubMed ID: 31493197
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers in the diagnosis and management of Alzheimer's disease.
Wurtman R
Metabolism; 2015 Mar; 64(3 Suppl 1):S47-50. PubMed ID: 25468144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
